This study was designed to compare the effects of levosimendan and dobutamine on hemodynamics
and clinical efficacy in patients with severe septic cardiomyopathy (left ventricular
ejection fraction [LVEF] ≤35%).
Prospective, single-blind, randomized controlled study.
Thirty patients with severe septic cardiomyopathy treated in our hospital's Department
of Critical Medicine from September 2018 to September 2021 were enrolled into this
These patients were randomly divided into the levosimendan group and dobutamine group.
LVEF, cardiac index (CI), stroke volume index (SVI), systemic vascular resistance
index (SVRI), heart rate (HR), norepinephrine dose (NED), and lactate (Lac) at the
time of enrollment and the 24th hour were compared, along with myocardial injury markers
on the third day, C-reactive protein (CRP), mechanical ventilation time, length of
intensive care unit (ICU) stay, cost, and 28-day mortality. The primary outcome was 28-day
Measurements & Main Results
At the 24th hour after treatment, the CI, LVEF, SVI, and fluid volume were found to
be higher in the levosimendan group than in the dobutamine group, while the dose of
norepinephrine was lower in the former than the latter group. On the third day of
treatment, cardiac troponin I (cTnI) in the levosimendan group was lower than that
in the dobutamine group. While the differences in 28-day mortality, ICU stay, and
ICU treatment cost between the two groups were not statistically significant, the
ventilator application time of the levosimendan group was significantly shorter than
that of the dobutamine group.
Compared with dobutamine, levosimendan is more effective at improving cardiac function,
reducing myocardial injury, and reducing mechanical ventilation time in patients with
severe septic cardiomyopathy.